Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.54 |
| ▸ | MAPT | P10636 | 9/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 8/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4996828 | 0.94 | ALDH1A1 (0.56) | FDPSALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL4996441 | 0.94 | FDPS (0.69) | FDPSALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL30802598 | 0.89 | FDPS (0.71) | FDPSALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL16360861 | 0.89 | FDPS (0.71) | FDPSALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL31268362 | 0.89 | FDPS (0.71) | FDPSALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL5370784 | 0.88 | FDPS (0.49) | FDPSALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL9671488 | 0.88 | FDPS (0.49) | FDPSALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL482374 | 0.87 | FDPS (0.77) | FDPSALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL2552700 | 0.87 | FDPS (0.48) | FDPSALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL9673508 | 0.87 | ALDH1A1 (0.54) | FDPSALDH1A1MAPTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371773-B2 | Breast cancer resistance protein (BCRP) inhibitor | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2008-05-13 | — | — | US | disclosed |
| US-20060128636-A1 | Breast cancer resistance protein (bcrp) inhibitor | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1591117-A1 | BREAST CANCER RESISTANCE PROTEIN (BCRP) INHIBITOR | Kabushiki Kaisha Yakult Honsha (JP) | 2005-11-02 | — | — | EP | disclosed |
| EP-0761672-B1 | Cephalosporins containing in position 7 a substituted benzyloxyimino radical, processes for their preparation and intermediates for their preparation, their use as medicaments | AVENTIS PHARMA SA (FR) | 2001-11-07 | — | — | EP | disclosed |
| US-5712266-A | Cephalosporins | ROUSSEL UCLAF (FR) | 1998-01-27 | — | — | US | disclosed |
| US-5710147-A | ANTIBIOTICS | ROUSSEL UCLAF (FR) | 1998-01-20 | — | — | US | disclosed |
| EP-0761672-A1 | Cephalosporin containing in position 7 a substituted benzyloxyimino radical, processes for their preparation and intermediates for their preparation, their use as medicaments | ROUSSEL UCLAF (FR) | 1997-03-12 | — | — | EP | disclosed |
| EP-0693496-A1 | Novel cephalosporins having a substituted benzyloxyimino radical in position 7, process for their preparation and their use as medicaments | ROUSSEL UCLAF (FR) | 1996-01-24 | — | — | EP | disclosed |
| EP-0241901-B1 | Cephalosporin derivatives, processes for their preparation and antibacterial agents | BANYU PHARMA CO LTD (JP) | 1994-08-24 | — | — | EP | disclosed |
| EP-0346465-B1 | 1-CARBOXY-1-VYNILOXYIMINOAMINOTHIAZOLE CEPHALOSPORING DERIVATIVES AND PROCESS FOR THEIR PREPARATION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-08-11 | — | — | EP | disclosed |
| US-5225406-A | Antibiotics | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-07-06 | — | — | US | disclosed |
| EP-0238061-B1 | CEPHALOSPORIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND ANTIBACTERIAL AGENTS | Banyu Pharmaceutical Co., Ltd. (JP) | 1992-10-21 | — | — | EP | disclosed |
| US-5084453-A | Antibiotics, bactericides | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1992-01-28 | — | — | US | disclosed |
| US-5061794-A | Effective against pseudomonads | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1991-10-29 | — | — | US | disclosed |
| US-4988687-A | Thiazoleoxyimineacetamido carboxymethylpyridinium derivatives of cephalosporins | BANYU PHARMACEUTICAL COMPANY, LTD. (JP) | 1991-01-29 | — | — | US | disclosed |
| US-4880797-A | THIAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1989-11-14 | — | — | US | disclosed |
| EP-0241901-A2 | Cephalosporin derivatives, processes for their preparation and antibacterial agents | Banyu Pharmaceutical Co., Ltd. (JP) | 1987-10-21 | — | — | EP | disclosed |
| EP-0238061-A2 | Cephalosporin derivatives, processes for their preparation and antibacterial agents | Banyu Pharmaceutical Co., Ltd. (JP) | 1987-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128636-A1 | Breast cancer resistance protein (bcrp) inhibitor | ABCC1, OSBP, OSBPL3 | FDPS 993/4885ALDH1A1 1336/4885MAPT 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.